AUTHOR=Hou Guozhu , Zhang Yuwei , Liu Yu , Wang Peipei , Xia Weibo , Xing Xiaoping , Huo Li , Li Fang , Jing Hongli 

TITLE=Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.811209

DOI=10.3389/fonc.2022.811209

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>The purpose of this study is to compare the sensitivity of <sup>68</sup>Ga-DOTA-JR11 and <sup>68</sup>Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced osteomalacia (TIO) and investigate if <sup>68</sup>Ga-DOTA-JR11 PET/CT can identify the culprit tumor of TIO in multiple suspicious lesions in <sup>68</sup>Ga-DOTA-TATE PET/CT.</p></sec><sec><title>Methods</title><p>A total of 19 patients with suspected TIO were prospectively recruited in this study. Each patient underwent whole-body PET/CT scan 40–60 min postinjection using <sup>68</sup>Ga-DOTA-TATE and <sup>68</sup>Ga-DOTA-JR11 on the same PET/CT, respectively in sequence, and on consecutive days. The diagnosis of TIO was confirmed by the combination of the postsurgical pathological results of the tumor and clinical information.</p></sec><sec><title>Results</title><p>Among the 19 patients with TIO who were included in this study, culprit tumors from all patients were confirmed pathologically. <sup>68</sup>Ga-DOTA-TATE PET/CT positively identified the causative tumor in 18/19 patients, whereas <sup>68</sup>Ga-DOTA-JR11 PET/CT was positive in 11/19 patients (94.7% vs. 57.9%, respectively; <italic>p</italic> &lt; 0.05). <sup>68</sup>Ga-DOTA-TATE PET/CT demonstrated more than one increased focal activity in 7 patients for a total of 16 lesions (3 lesions each in 2 patients and 2 lesions each in the rest 5 patients). However, seven of these 16 lesions showed concordant results on <sup>68</sup>Ga-DOTA-JR11 PET/CT by demonstrating increased activity (one lesion in each of the 7 patients). The surgical specimens of the lesions in these 7 patients confirmed the phosphaturic mesenchymal tumor. A total of 11 culprit tumors were positive in both <sup>68</sup>Ga-DOTA-TATE and <sup>68</sup>Ga-DOTA-JR11 PET/CT. The SUVmax of 11 culprit tumors was significantly higher on <sup>68</sup>Ga-DOTA-TATE PET/CT compared with that on <sup>68</sup>Ga-DOTA-JR11 PET/CT (17.8 ± 12.5 vs. 6.8 ± 6.2; <italic>p</italic> &lt; 0.05).</p></sec><sec><title>Conclusions</title><p><sup>68</sup>Ga-DOTA-TATE PET/CT is more sensitive to <sup>68</sup>Ga-DOTA-JR11 PET/CT in the detection of the culprit tumor of TIO. However, <sup>68</sup>Ga-DOTA-JR11 PET/CT might be helpful to identify the tumor in multiple suspicious lesions in <sup>68</sup>Ga-DOTA-TATE PET/CT.</p></sec><sec><title>Clinical Trial Registration</title><p><uri xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</uri>, identifier NCT 04689893.</p></sec>